Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

Inventiva, a clinical-stage biopharmaceutical company specializing in oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other serious health conditions, has disclosed the timetable for its 2024 full-year financial results. The company is headquartered in Daix, France, and is publicly traded on both Euronext Paris and NASDAQ under the ticker IVA.

The results will be made available on March 26, 2025, at 4:00 PM New York time (9:00 PM Paris time). Following this announcement, Inventiva's management team, including CEO Frédéric Cren and CFO Jean Volatier, will host a conference call and webcast on March 27, 2025, at 8:00 AM New York time (1:00 PM Paris time). This session aims to provide insights into the company’s financial performance alongside a Q&A segment for stakeholders.

To participate in the conference call, interested parties must register in advance to receive the necessary access information. The replay of the conference call and the corresponding presentation will also be available on the company’s website post-event.

Inventiva is actively engaged in the evaluation of its most notable drug candidate, lanifibranor, a pan-PPAR agonist currently in pivotal Phase 3 clinical trials for adult patients with MASH. The company's dedicated team comprises about 90 professionals with expertise in various scientific fields, supported by a substantial library of approximately 240,000 pharmacologically relevant molecules.

For more information, the company’s communication channels are accessible via email and phone for media and investor inquiries. This financial announcement marks a significant moment for Inventiva as it advances toward fulfilling unmet medical needs in the biopharmaceutical landscape.

As Inventiva (Euronext Paris and NASDAQ: IVA) prepares to announce its 2024 full-year financial results, scheduled for release on March 26, 2025, investors should closely watch the developments leading up to the results. The company's focus on metabolic dysfunction-associated steatohepatitis (MASH) positions it uniquely in a market with significant unmet medical needs, suggesting potential for substantial growth.

Investors should consider several critical factors in their analysis. Firstly, the upcoming financial results will likely provide insights into the company's ongoing Phase 3 clinical trial of lanifibranor, a novel pan-PPAR agonist. The outcome of this trial and its subsequent demonstration of efficacy could significantly impact stock performance. Strong results may bolster investor confidence and drive the stock price upward, while disappointing outcomes could lead to increased volatility.

Secondly, the planned conference call on March 27, featuring CEO Frédéric Cren and CFO Jean Volatier, is a crucial opportunity for management to articulate future strategies, projections, and insights into the competitive landscape. Investors should pay attention to any guidance provided regarding projected revenues, expenditures on R&D, and timelines for product development, as these details can influence market sentiment.

Furthermore, given Inventiva's robust library of pharmacologically relevant molecules and experienced scientific team, there’s a strong foundation for creating additional therapies beyond MASH. Investors should assess how the market views these assets and the potential for diversifying beyond its lead candidate.

In summary, while the stock may exhibit volatility around the announcement, long-term investors could find opportunities if Inventiva demonstrates solid results and a compelling strategy for future growth. Keep an eye on both the financial results and ongoing trial updates for informed decision-making.